Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis

Xin Jian Li, Choon Kiat Ong, Yun Cao, Yan Qun Xiang, Jian Yong Shao, Aikseng Ooi, Li Xia Peng, Wen Hua Lu, Zhongfa Zhang, David Petillo, Li Qin, Ying Na Bao, Fang Jing Zheng, Claramae Shulyn Chia, N. Gopalakrishna Iyer, Tie Bang Kang, Yi Xin Zeng, Khee Chee Soo, Jeffrey M. Trent, Bin Tean TehChao Nan Qian

Research output: Contribution to journalArticle

Abstract

Nasopharyngeal carcinoma (NPC) is known for its high-metastatic potential. Here we report the identification of the proteoglycan serglycin as a functionally significant regulator of metastasis in this setting. Comparative genomic expression profiling of NPC cell line clones with high- and low-metastatic potential revealed the serglycin gene (SRGN) as one of the most upregulated genes in highly metastatic cells. RNAi-mediated inhibition of serglycin expression blocked serglycin secretion and the invasive motility of highly metastatic cells, reducing metastatic capacity in vivo. Conversely, serglycin overexpression in poorly metastatic cells increased their motile behavior and metastatic capacity in vivo. Growth rate was not influenced by serglycin in either highly or poorly metastatic cells. Secreted but not bacterial recombinant serglycin promoted motile behavior, suggesting a critical role for glycosylation in serglycin activity. Serglycin inhibition was associated with reduced expression of vimentin but not other epithelial-mesenchymal transition proteins. In clinical specimens, serglycin expression was elevated significantly in liver metastases from NPC relative to primary NPC tumors. We evaluated the prognostic value of serglycin by immunohistochemical staining of tissue microarrays from 263 NPC patients followed by multivariate analyses. High serglycin expression in primary NPC was found to be an unfavorable independent indicator of distant metastasis-free and disease-free survival. Our findings establish that glycosylated serglycin regulates NPC metastasis via autocrine and paracrine routes, and that it serves as an independent prognostic indicator of metastasis-free survival and disease-free survival in NPC patients.

Original languageEnglish (US)
Pages (from-to)3162-3172
Number of pages11
JournalCancer Research
Volume71
Issue number8
DOIs
StatePublished - Apr 15 2011
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Nasopharyngeal carcinoma
serglycin
Theranostic Nanomedicine
Disease-Free Survival
Epithelial-Mesenchymal Transition
Vimentin
Proteoglycans
RNA Interference
Glycosylation
Genes
Multivariate Analysis
Clone Cells
Staining and Labeling
Cell Line
Liver
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Li, X. J., Ong, C. K., Cao, Y., Xiang, Y. Q., Shao, J. Y., Ooi, A., ... Qian, C. N. (2011). Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Research, 71(8), 3162-3172. https://doi.org/10.1158/0008-5472.CAN-10-3557

Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. / Li, Xin Jian; Ong, Choon Kiat; Cao, Yun; Xiang, Yan Qun; Shao, Jian Yong; Ooi, Aikseng; Peng, Li Xia; Lu, Wen Hua; Zhang, Zhongfa; Petillo, David; Qin, Li; Bao, Ying Na; Zheng, Fang Jing; Chia, Claramae Shulyn; Iyer, N. Gopalakrishna; Kang, Tie Bang; Zeng, Yi Xin; Soo, Khee Chee; Trent, Jeffrey M.; Teh, Bin Tean; Qian, Chao Nan.

In: Cancer Research, Vol. 71, No. 8, 15.04.2011, p. 3162-3172.

Research output: Contribution to journalArticle

Li, XJ, Ong, CK, Cao, Y, Xiang, YQ, Shao, JY, Ooi, A, Peng, LX, Lu, WH, Zhang, Z, Petillo, D, Qin, L, Bao, YN, Zheng, FJ, Chia, CS, Iyer, NG, Kang, TB, Zeng, YX, Soo, KC, Trent, JM, Teh, BT & Qian, CN 2011, 'Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis', Cancer Research, vol. 71, no. 8, pp. 3162-3172. https://doi.org/10.1158/0008-5472.CAN-10-3557
Li, Xin Jian ; Ong, Choon Kiat ; Cao, Yun ; Xiang, Yan Qun ; Shao, Jian Yong ; Ooi, Aikseng ; Peng, Li Xia ; Lu, Wen Hua ; Zhang, Zhongfa ; Petillo, David ; Qin, Li ; Bao, Ying Na ; Zheng, Fang Jing ; Chia, Claramae Shulyn ; Iyer, N. Gopalakrishna ; Kang, Tie Bang ; Zeng, Yi Xin ; Soo, Khee Chee ; Trent, Jeffrey M. ; Teh, Bin Tean ; Qian, Chao Nan. / Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. In: Cancer Research. 2011 ; Vol. 71, No. 8. pp. 3162-3172.
@article{998d4453563e4902b3884229fc6b7959,
title = "Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis",
abstract = "Nasopharyngeal carcinoma (NPC) is known for its high-metastatic potential. Here we report the identification of the proteoglycan serglycin as a functionally significant regulator of metastasis in this setting. Comparative genomic expression profiling of NPC cell line clones with high- and low-metastatic potential revealed the serglycin gene (SRGN) as one of the most upregulated genes in highly metastatic cells. RNAi-mediated inhibition of serglycin expression blocked serglycin secretion and the invasive motility of highly metastatic cells, reducing metastatic capacity in vivo. Conversely, serglycin overexpression in poorly metastatic cells increased their motile behavior and metastatic capacity in vivo. Growth rate was not influenced by serglycin in either highly or poorly metastatic cells. Secreted but not bacterial recombinant serglycin promoted motile behavior, suggesting a critical role for glycosylation in serglycin activity. Serglycin inhibition was associated with reduced expression of vimentin but not other epithelial-mesenchymal transition proteins. In clinical specimens, serglycin expression was elevated significantly in liver metastases from NPC relative to primary NPC tumors. We evaluated the prognostic value of serglycin by immunohistochemical staining of tissue microarrays from 263 NPC patients followed by multivariate analyses. High serglycin expression in primary NPC was found to be an unfavorable independent indicator of distant metastasis-free and disease-free survival. Our findings establish that glycosylated serglycin regulates NPC metastasis via autocrine and paracrine routes, and that it serves as an independent prognostic indicator of metastasis-free survival and disease-free survival in NPC patients.",
author = "Li, {Xin Jian} and Ong, {Choon Kiat} and Yun Cao and Xiang, {Yan Qun} and Shao, {Jian Yong} and Aikseng Ooi and Peng, {Li Xia} and Lu, {Wen Hua} and Zhongfa Zhang and David Petillo and Li Qin and Bao, {Ying Na} and Zheng, {Fang Jing} and Chia, {Claramae Shulyn} and Iyer, {N. Gopalakrishna} and Kang, {Tie Bang} and Zeng, {Yi Xin} and Soo, {Khee Chee} and Trent, {Jeffrey M.} and Teh, {Bin Tean} and Qian, {Chao Nan}",
year = "2011",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-10-3557",
language = "English (US)",
volume = "71",
pages = "3162--3172",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis

AU - Li, Xin Jian

AU - Ong, Choon Kiat

AU - Cao, Yun

AU - Xiang, Yan Qun

AU - Shao, Jian Yong

AU - Ooi, Aikseng

AU - Peng, Li Xia

AU - Lu, Wen Hua

AU - Zhang, Zhongfa

AU - Petillo, David

AU - Qin, Li

AU - Bao, Ying Na

AU - Zheng, Fang Jing

AU - Chia, Claramae Shulyn

AU - Iyer, N. Gopalakrishna

AU - Kang, Tie Bang

AU - Zeng, Yi Xin

AU - Soo, Khee Chee

AU - Trent, Jeffrey M.

AU - Teh, Bin Tean

AU - Qian, Chao Nan

PY - 2011/4/15

Y1 - 2011/4/15

N2 - Nasopharyngeal carcinoma (NPC) is known for its high-metastatic potential. Here we report the identification of the proteoglycan serglycin as a functionally significant regulator of metastasis in this setting. Comparative genomic expression profiling of NPC cell line clones with high- and low-metastatic potential revealed the serglycin gene (SRGN) as one of the most upregulated genes in highly metastatic cells. RNAi-mediated inhibition of serglycin expression blocked serglycin secretion and the invasive motility of highly metastatic cells, reducing metastatic capacity in vivo. Conversely, serglycin overexpression in poorly metastatic cells increased their motile behavior and metastatic capacity in vivo. Growth rate was not influenced by serglycin in either highly or poorly metastatic cells. Secreted but not bacterial recombinant serglycin promoted motile behavior, suggesting a critical role for glycosylation in serglycin activity. Serglycin inhibition was associated with reduced expression of vimentin but not other epithelial-mesenchymal transition proteins. In clinical specimens, serglycin expression was elevated significantly in liver metastases from NPC relative to primary NPC tumors. We evaluated the prognostic value of serglycin by immunohistochemical staining of tissue microarrays from 263 NPC patients followed by multivariate analyses. High serglycin expression in primary NPC was found to be an unfavorable independent indicator of distant metastasis-free and disease-free survival. Our findings establish that glycosylated serglycin regulates NPC metastasis via autocrine and paracrine routes, and that it serves as an independent prognostic indicator of metastasis-free survival and disease-free survival in NPC patients.

AB - Nasopharyngeal carcinoma (NPC) is known for its high-metastatic potential. Here we report the identification of the proteoglycan serglycin as a functionally significant regulator of metastasis in this setting. Comparative genomic expression profiling of NPC cell line clones with high- and low-metastatic potential revealed the serglycin gene (SRGN) as one of the most upregulated genes in highly metastatic cells. RNAi-mediated inhibition of serglycin expression blocked serglycin secretion and the invasive motility of highly metastatic cells, reducing metastatic capacity in vivo. Conversely, serglycin overexpression in poorly metastatic cells increased their motile behavior and metastatic capacity in vivo. Growth rate was not influenced by serglycin in either highly or poorly metastatic cells. Secreted but not bacterial recombinant serglycin promoted motile behavior, suggesting a critical role for glycosylation in serglycin activity. Serglycin inhibition was associated with reduced expression of vimentin but not other epithelial-mesenchymal transition proteins. In clinical specimens, serglycin expression was elevated significantly in liver metastases from NPC relative to primary NPC tumors. We evaluated the prognostic value of serglycin by immunohistochemical staining of tissue microarrays from 263 NPC patients followed by multivariate analyses. High serglycin expression in primary NPC was found to be an unfavorable independent indicator of distant metastasis-free and disease-free survival. Our findings establish that glycosylated serglycin regulates NPC metastasis via autocrine and paracrine routes, and that it serves as an independent prognostic indicator of metastasis-free survival and disease-free survival in NPC patients.

UR - http://www.scopus.com/inward/record.url?scp=79954613658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954613658&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-3557

DO - 10.1158/0008-5472.CAN-10-3557

M3 - Article

C2 - 21289131

AN - SCOPUS:79954613658

VL - 71

SP - 3162

EP - 3172

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -